当前位置: 首页 > 期刊 > 《医学信息》 > 2018年第5期
编号:13242986
肝移植围术期EPO应用的效果及安全性研究(3)
http://www.100md.com 2018年2月5日 《医学信息》 2018年第5期
     另外,EPO具有一定的器官保護功能[14-15],对机体供氧状况发挥重要的调控作用,EPO有益于肝次全切除术大鼠肝的肝脏保护和再生及缺血再灌注损伤[16],具有抗氧化、抗凋亡、促进血管生长等作用[17],是一种全身性的保护性细胞因子[2,18]。本研究中围术期未发现有高血压、纤维素蛋白溶解、头痛以及血栓形成等副作用出现。

    综上所述,同种异体肝移植贫血患者围术期使用rHuEPO促进红细胞动员,与对照组比较术中输血不增加,且有助于术后1个月贫血的明显改善,提示rHuEPO对肝移植贫血的重症患者安全、有效。

    参考文献:

    [1]De Santis GC,Brunetta DM,Nardo M,et al.Preoperative variables associated with transfusion requirements in orthotopic liver transplantation[J].TransfusApherSci,2014,50(1):99-105.
, 百拇医药
    [2]赵玲莉,耿惠,邓丽君,等.EPO的临床研究进展[J].青海医药杂志,2011,41(3):74-77.

    [3]张亚芳.促红细胞生成素在危重患者贫血治疗中的效果及安全性探讨[J].华夏医学,2013,26(3):492-494.

    [4]姚泰.生理学[M].第6版.北京:人民卫生出版社,2004:53.

    [5]Posluszny Jr JA,Napolitano LM.How do we treat life-threatening anemia in a Jehovah's Witness patient[J].Transfusion,2014,54(12):3026-3034.

    [6]Garcia JH,Coelho GR,FeitosaNeto BA,et al.Liver transplantation in Jehovah's Witnesses patients in a center of northeastern Brazil[J].ArqGastroenterol,2013,50(2):138-140.
, 百拇医药
    [7]de Araujo Azi LM,Lopes FM,Garcia LV.Postoperative management of severe acute anemia in a Jehovah's Witness[J].Transfusion,2014,54(4):1153-1157.

    [8]Brunetta DM,Kaufman J,DeSantis GC,et al.Severe Acute Anemia After Liver Transplantation in an Elderly Jehovah's Witness Treated With High-dose Erythropoietin and Ferric Carboxymaltose:A Case Report[J].Transplant Proc,2015,47(8):2548-2551.

    [9]虞德明,白亚强,刘文晶.促红细胞生成素在开颅动脉瘤夹闭术后脑缺血中的应用效果[J].重庆医学,2017,46(3):394-396.
, http://www.100md.com
    [10]朱栩宏,姜飞,杨晶,等.重组人促红细胞生成素及硫酸亚铁在Rh阴性骨盆骨折患者手术中的临床应用价值[J].中华实用诊断与治疗杂志,2017,31(3):284-286.

    [11]Weltert L,Rondinelli B,Bello R,et al.A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-blind randomized controlled trial[J].Transfusion,2015,55(7):1644-1654.

    [12]朱孔娟,袁莉,董河,等.EPO对脊柱外科病人围术期异体血需求和凝血功能的影响[J].青岛大学医学院学报,2015,51(5):517-520.

, 百拇医药     [13]宋作艳,袁莉,王世端,等.联合应用铁剂和促红细胞生成素对妇科贫血患者异体血需求的影响[J].解放军医学院学报,2014,35(4):316-318.

    [14]Lund A,Lundby C,Olsen NV.High-dose erythropoietin for tissue protection[J].Eur J Clin Invest, 2014,44(12):1230-1238.

    [15]Nangaku M.Tissue protection by erythropoietin:new findings in a moving field[J].Kidney Int ,2013,84(3):427-429.

    [16]Greif F,Ben-Ari Z,Taya R,et al.Dual effect of erythropoietin on liver protection and regeneration after subtotal hepatectomy in rats[J].Liver Transpl,2010,16(5):631-638.

    [17]Shander A,Javidroozi M,Naqvi S,et al.An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion(CME)[J].Transfusion ,2014,54(10):2688-2695.

    [18]Fischer JW.Landmark advances in development of erythropoietin[J].ExpBiolMed,2010,235(12):1398-1411., 百拇医药(贾鹏飞 袁莉 赵利鹏 臧运金 薛欣)
上一页1 2 3